Thomas Frogne

Summary

Publications

  1. ncbi Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors
    Thomas Frogne
    Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, Copenhagen, Denmark
    Breast Cancer Res 11:R11. 2009
  2. ncbi Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant
    Thomas Frogne
    Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
    Breast Cancer Res Treat 114:263-75. 2009
  3. ncbi Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance
    Katrine Sonne-Hansen
    Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, 2100 Copenhagen, Denmark
    Breast Cancer Res Treat 121:601-13. 2010
  4. ncbi Development of new predictive markers for endocrine therapy and resistance in breast cancer
    Katrine L Henriksen
    Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
    Acta Oncol 47:795-801. 2008

Collaborators

Detail Information

Publications4

  1. ncbi Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors
    Thomas Frogne
    Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, Copenhagen, Denmark
    Breast Cancer Res 11:R11. 2009
    ..In the present study we examined the importance of active HER signaling in breast tumor biopsies and paired metastases, by evaluating the expression of phosphorylated HER1, HER2, HER3, Erk, Akt and the total level of HER4 and HER2...
  2. ncbi Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant
    Thomas Frogne
    Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
    Breast Cancer Res Treat 114:263-75. 2009
    ..Our data support that a concerted action against EGFR, ErbB2 and ErbB3 may be required to obtain complete growth suppression of fulvestrant resistant cells...
  3. ncbi Breast cancer cells can switch between estrogen receptor alpha and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance
    Katrine Sonne-Hansen
    Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Strandboulevarden 49, 2100 Copenhagen, Denmark
    Breast Cancer Res Treat 121:601-13. 2010
    ..Further, upfront combination of endocrine therapy with pan-ErbB inhibition may postpone or even prevent development of treatment resistance...
  4. ncbi Development of new predictive markers for endocrine therapy and resistance in breast cancer
    Katrine L Henriksen
    Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
    Acta Oncol 47:795-801. 2008
    ..This paper describes the use of preclinical models to identify mechanisms and new markers for endocrine sensitivity and resistance and the translation of these data to clinical utility...